CHUNLI MEDICAL(SH:688236)2023-04-27 16:00Financial Performance - Total revenue for Q1 2023 was ¥246,355,024.32, a decrease of 4.3% compared to ¥257,113,202.13 in Q1 2022[7] - The company's operating revenue for Q1 2023 was CNY 246,355,024.32, representing a decrease of 4.18% compared to the same period last year[35] - The net profit attributable to shareholders of the listed company was CNY 55,861,404.05, down 24.53% year-on-year[35] - The net profit for Q1 2023 was CNY 55,861,404.05, a decrease of 24.5% compared to CNY 74,021,366.53 in Q1 2022[44] - Operating profit for Q1 2023 was CNY 62,341,671.90, down 26.0% from CNY 84,279,091.21 in the same period last year[44] - Total profit for Q1 2023 reached CNY 62,225,078.79, a decline of 25.0% compared to CNY 82,950,225.44 in Q1 2022[44] Operating Costs and Expenses - Total operating costs increased to ¥183,535,965.29 in Q1 2023, up 7.1% from ¥170,342,269.72 in Q1 2022[7] - Research and development expenses for Q1 2023 were ¥33,270,315.66, slightly up from ¥33,114,231.75 in Q1 2022[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 33.36% to CNY 49,607,213.75, primarily due to the impact of "volume-based procurement" and increased R&D investments[38] - The net cash flow from operating activities was negative at CNY -120,197,574.28, indicating increased cash outflows primarily due to higher R&D expenditures and raw material costs[35] Cash and Liquidity - Cash and cash equivalents at the end of Q1 2023 were ¥838,344,639.97, down from ¥1,025,826,965.44 at the end of Q1 2022[10] - The company reported a net decrease in cash and cash equivalents of ¥118,849,021.05 in Q1 2023[10] - Cash inflow from operating activities was CNY 212,802,558.95, slightly up from CNY 209,155,705.21 in Q1 2022, representing a growth of 1.3%[45] - Total cash flow from operating, investing, and financing activities indicates a challenging liquidity position for the company[56] - The company is focusing on improving cash flow management and reducing operational losses in future quarters[56] Shareholder Information - The number of common shareholders at the end of the reporting period was 5,766[1] - The largest shareholder, Shi Chunbao, holds 29.88% of shares, totaling 114,840,685 shares[2] - The total equity attributable to shareholders remained stable at ¥384,280,000.00[6] - The total equity attributable to shareholders of the listed company increased by 2.05% to CNY 2,775,561,183.72 compared to the end of the previous year[36] - The total equity attributable to shareholders of the parent company increased to CNY 2,775,561,183.72 from CNY 2,719,699,779.72, reflecting a growth of 2.1%[53] Assets and Liabilities - Total liabilities decreased to ¥615,416,974.31 in Q1 2023 from ¥690,066,911.19 in Q1 2022[6] - The company's total assets as of March 31, 2023, were CNY 3,391,412,670.08, a slight decrease of 0.54% from the end of the previous year[36] - The company's total liabilities decreased slightly, reflecting a stable financial position despite the challenges faced in the market[36] - The total liabilities and equity amounted to CNY 3,391,412,670.08, a slight decrease from CNY 3,409,766,690.91 in the previous year[53] Strategic Focus - The company emphasized its commitment to new product and technology development as part of its long-term strategic planning[38] - The management team is committed to strategic investments to enhance long-term growth despite current cash flow challenges[56]